Cinvanti - (130 mg/18 mL; Intravenous Emulsion)

Generic Name	Aprepitant	Innovator	Heron Therapeutics
Dosage	130 mg/18 mL; Intravenous Emulsion	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Cinvanti is a substance P/neurokinin-1 (NK 1) receptor antagonist,indicated in adults, in combination with other antiemetic agents, for the prevention of:  acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.  nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
********* ****	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*****	** \ **	*** **, ****	*******	****	*** ****** *** **, ****
******** ******	** \ ** (***** ***)	*** **, ****	*******	********* ********	*** ****** *** ****

Chronology Of Events